Intrauterine Device Use May Reduce Incidence of Ovarian Cancer
Novel noncontraceptive benefit seen for all intrauterine devices.
Gynecologic, Ovarian, and Cervical Cancer News
GYNECOLOGIC CANCER ADVISOR
Pain Associated With Quality of Life and Survival for Patients With Recurrent Ovarian Cancer
Researchers sought to analyze how pain management affects quality of life and overall survival for patients with recurrent ovarian cancer.
Psychologic Distress Linked to Cervical Cancer Mortality
Risk up with diagnosis of stress-related disorders or an occurrence of stressful life events around diagnosis.
Germline BRCA2 Mutations Linked to Pediatric Lymphomas
Survivors of NHL should be offered genetic counseling.
Black Women With Cervical Cancer Less Likely to Receive Brachytherapy
Black women with cervical cancer were less likely to receive brachytherapy and had poorer survival, suggesting brachytherapy may mediate survival outcomes.
Zejula Gets Priority Review for Late Stage Ovarian Cancer Indication
The sNDA is supported by data from the multicenter phase 2 QUADRA trial that evaluated the safety and activity of Zejula in 463 patients.
Higher Surgical Volume May Improve Outcomes in Cervical Cancer
Surgery at high-volume centers is associated with decreased local recurrence risk and improved survival for women with early-stage cervical cancer.
Mirvetuximab Soravtansine Data Lacking for FDA’s Accelerated Approval in Ovarian CA
Mirvetuximab soravtansine is the first folate receptor alpha-targeting antibody-drug conjugate.
Experts Recommend Cytologic Test Every 3 Years, High-Risk HPV Test Every 5 Years
A new study challenges the recommended use of cotesting for cervical cancer screening.
Intraperitoneal Chemotherapy Fails to Improve Outcomes in Advanced Ovarian Carcinoma
When paired with bevacizumab, neither intraperitoneal delivery of carboplatin nor cisplatin improved outcomes for patients with advanced ovarian carcinoma compared with intravenous delivery.
CDC: Recent Decline Seen in High-Grade Cervical Lesions
The number of cervical precancers (CIN2+ cases) in the United States declined from 2008 to 2016.
Late-Line Niraparib in Advanced Ovarian Cancer: A Continuum of Clinical Benefit in Subgroups Characterized by Clinical and Molecular Biomarkers
More accurate biomarkers are needed to better define subgroups of patients with ovarian cancer who are most likely to benefit from late-line niraparib.
Genetic Testing Underused in Breast, Ovarian Cancer
Pathogenic variants ID’d in 7.8 percent of patients with breast cancer, 14.5 percent with ovarian cancer
Chemoimmunotherapy Confers Survival Benefit in Patients With HPV16-Induced Cervical Cancer
Coadministration of the HPV16-specific vaccine, ISA101, with chemotherapy was found to be associated with stronger tumor immunity.
Dendritic Cell Vaccination in Ovarian Cancer May Induce Long-Lasting Antitumor Immunity
Median OS was significantly improved when dendritic cell vaccination therapy was added to standard second-line chemo in platinum-sensitive, relapsed ovarian cancer.
Improved Quality of Life After Concurrent Surgery for Endometrial Cancer and Incontinence
Concurrent surgery for cancer and stress urinary incontinence was associated with significantly improved QoL for women with early endometrial neoplasms and urinary stress incontinence.
TSR-042, a PD-1 Inhibitor, for Recurrent or Advanced Endometrial Cancer
According to researchers, responses to TSR-042 were seen in subgroups of patients with disease characterized as microsatellite instability (MSI)-high and MSI-low.
Atezolizumab Plus Bevacizumab in Advanced Cervical Cancer
Median PFS was only 2.9 months for women with advanced cervical cancer receiving the combination of atezolizumab plus bevacizumab.
Pembrolizumab Plus Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
A clinical benefit rate of 86% was observed in a phase 2 trial of pembrolizumab plus chemotherapy in patients with recurrent, platinum-resistant ovarian cancer.
Promising Early Results for Tisotumab Vedotin in Advanced Cervical Cancer
According to researchers, responses to tisotumab vedotin were seen in women with refractory advanced cervical cancer.
Want to read more?
Please login or register first to view this content.
Next post in Gynecologic Cancer
